【一品红：AR882目前尚未实现上市销售未产生销售收入】一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。

金融界2025-04-14

一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527690163?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-14 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527690163","market":"hk","top_or_hot":-1,"title":"【一品红：AR882目前尚未实现上市销售 未产生销售收入】一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。","media":"金融界","content":"<div>\n<p>一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/04/14204249532143.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【一品红：AR882目前尚未实现上市销售 未产生销售收入】一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【一品红：AR882目前尚未实现上市销售 未产生销售收入】一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-14 20:42 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/04/14204249532143.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/04/14204249532143.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300723","symbol_name":"一品红","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/04/14204249532143.shtml","article_id":"2527690163","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527690163","pubTimestamp":1744634526,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","300723":"一品红","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK0239":"医药制造"},"translate_title":"[Poinsettia: AR882 has not yet been marketed and sold without generating sales revenue] Poinsettia (300723. SZ) announced a change. The company's cooperative innovative drug AR882 still needs to carry out phase III clinical research at home and abroad and be approved by the drug evaluation department. It can only be put on the market for sale, and it is uncertain whether it can pass the final approval of the regulatory authorities, be approved for marketing and the time of marketing. AR882 has not yet been listed and sold, and has not generated sales revenue, which will not have a significant ","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"300723":1,"06978":1},"content_text":"一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527690163","isCrawlerRequest":true}